First Patients Enrolled in the Gore RELINE MAX Clinical Study
108 patient trial to add evidence for treatment of in-stent restenosis using the GORE® VIABAHN® Endoprosthesis
Unique Biomaterial for Hernia Repair Receives FDA 510K Clearance
GORE® SYNECOR Biomaterial combines strength of PTFE with the tissue-building scaffold of GORE® BIO-A® Web to create an improved device for hernia repair
GORE® VIABAHN® Endoprosthesis Marks 20 Years of Proven Performance
Market-leading stent-graft has evolved to address range of indications, patient needs
FDA Approves First Balloon Expandable Stent Graft for Use in the Iliac Artery
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Provides Improved Outcomes in Real-World Peripheral Arterial Disease Cases
GORE® TIGRIS® Vascular Stent Gains Health Canada Approval for Treatment of Peripheral Artery Disease
Novel device combines proven technology with modern adaptations to provide support in even the most challenging anatomies
W. L. Gore & Associates Receives Innovative Technology Designation from Vizient, Inc. for GORE® SYNECOR Biomaterial
Designation recognizes products that bring improvements to the healthcare industry
Study Confirms GORE® BIO-A® Tissue Reinforcement a Proven Alternative to Biologics in Hernia Repair
Two-year study demonstrates improved patient satisfaction with Gore material
Gore Receives Health Canada Approval for GORE® VIABAHN® Endoprosthesis Innovations, Treating Peripheral Vascular Disease
Longer and Lower Profile Options Now Available in Canada to Treat More Patient Anatomies
Final Subject Enrolled in Early Feasibility Study of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis
Antegrade iteration accepted into study – advancing this branched, all-in-one system
One-Year Results in Japanese Clinical Study Affirms the GORE® VIABAHN® Endoprosthesis as a Device-of-Choice for Treating Complex SFA Disease
New clinical study shows excellent patency consistent with previous study results of self-expanding stent-graft in long, complex SFA lesions